National Beverage Corp. vs Twist Bioscience Corp — how do they compare? National Beverage Corp. trades at $30.9 (market cap $2.91B), while Twist Bioscience Corp trades at $123 (market cap $7.82B). The key difference: Twist Bioscience Corp is far larger — about 2.7× National Beverage Corp.'s market cap, and Twist Bioscience Corp is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals.
| FIZZ | TWST | |
|---|---|---|
Market Cap | $2.91B | $7.82B |
Sector | Consumer Cyclical | Health |
52-Week High | $46.75 | $124.88 |
52-Week Low | $30.53 | $24.16 |
Enterprise Value | $2.62B | $7.75B |
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $32.13, up 0.53% today, with neutral technical signals and mixed earnings performance. The company reported $1.20B revenue and $186.82M net income for 2025, maintaining strong profitability margins. Recent news highlights a special $3.25 dividend announcement amid concerns about LaCroix brand stagnation and competitive pressures.
The stock faces headwinds from declining volumes and muted growth prospects, offset by shareholder returns via dividends. Analyst sentiment is cautious with 50% sell ratings. Key risks include consumer weakness and tariff impacts, while valuation at 15.84x P/E appears reasonable given current fundamentals.
Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.
The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.
Trailing returns across standard periods
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →